Sermorelin

Receptor pharmacology

Sermorelin is investigated as an agonist at the GHRH receptor, a class B G-protein-coupled receptor expressed on pituitary somatotrophs. Binding studies and cell-based assays have examined how the amidated 1–29 fragment engages the receptor's extracellular domain, activates adenylate cyclase and raises intracellular cyclic AMP, which in turn is reported to promote transcription and release of stored growth hormone.

Pulsatility and axis feedback

Comparative and structure–activity work

• Comparison with longer-acting analogues such as CJC-1295 and tesamorelin to map how sequence modifications alter enzymatic stability
• Combination studies with ghrelin-receptor peptides such as ipamorelin, where the two receptor classes are examined for additive signalling in vitro
• Structure–activity analysis of the N-terminal residues, which are highly sensitive to substitution and to dipeptidyl peptidase-4 cleavage

Model systems and endpoints

Keep the sealed vial at −20 °C and allow it to reach room temperature before opening so condensation does not settle on the powder. Reconstitute in the laboratory with bacteriostatic or sterile water directed down the vial wall, then swirl gently — vortexing and shaking can shear and denature the peptide. Store the reconstituted solution at 2–8 °C, protected from light, and record the preparation date on the vial. Avoid repeated freeze–thaw cycles; aliquot instead if a study runs over several sessions. Handle with gloves in a clean workspace, and follow your institution's chemical hygiene plan for storage, labelling and disposal.